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We addressed the fourth point made by Piessen et al2 by
constructing propensity scores as another adjustment method
to reach what they suggest to be “comprehensively robust con-
clusions.” HRs associated with SRCs in models including SRCs
alone (HR, 1.04; 95%CI, 0.98 to 1.11; SRC plus propensity score
deciles: HR, 1.01; 95% CI, 0.94 to 1.09; and SRC plus propensity
score deciles plus tumor grade: HR, 1.00; 95% CI, 0.94 to 1.08)
all suggest no independent contribution of SRC to mortality.
Thus, the suggestions of Piessen et al further support our con-
clusion regarding the central role of differences in presentation
between SRC and gastric AC tumors in the United States.
Finally, we note that it is unclear whether the statistical models
estimated in an earlier article by Piessen et al,3 in which mortality
differences were demonstrated as a function of SRC, simultaneously
adjusted for differences in presentation of the kind we adjusted for in
this study. Our findings demonstrate the results from a robust na-
tional database reflecting the diversity of the population in theUnited
States. We look forward to the results from France.
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Acute Oxaliplatin-Induced
Thrombotic Thrombocytopenic
Purpura: A Case Report and Results
From a Cytoflourimetric Assay of
Platelet Fibrinogen Receptor
TO THE EDITOR: In their recent article, Niu andMims1 described
a patient with oxaliplatin-induced thrombotic thrombocytopenic
purpura (TTP). Clinical evidence was supported by the ADAMTS13
(a disintegrin-like metalloprotease with thrombospondin type I mo-
tifs)metalloproteinase assay, and the authors postulated the role of an
immune process as the principal underlyingmechanism.We recently
had a similar experience with a 68-year-old woman with liver and
peritoneal metastases from colon cancer. The experimental aspect of
our experience focused mainly on the sudden drop in platelet count
andon the possibility of performing an affordable anddynamic plate-
let function test that could provide further valuable pathogenetic
insights into the problem.
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Fig 1. (A) Fluorescence intensity of
PAC-1 (FITC) assessed in the patient’s
blood at baseline and (B) after incubation
with oxaliplatin 0.5 mmol/L for 10 min-
utes. (C) Percentage of PAC-1–positive
platelets before (blue bar) and after (gold
bar) oxaliplatin incubation in three healthy
donors and in the patient’s blood (mean
and standard deviations are reported).
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Thepatient received adjuvant chemotherapywith infusional flu-
orouracil, leucovorin, and oxaliplatin (FOLFOX) in 2006, with no
adverse effects. In 2011, after evidence of relapsed disease, additional
cycles of chemotherapy with FOLFOX were administered. The first
two cycles were concluded with no adverse effects, and routine blood
tests were normal (platelet count, 194  103/L; international nor-
malized ratio [INR], 1.06). However, 30 minutes after the third ox-
aliplatin infusion, the patient experienced severe bleeding of the gums
andnail beds, epistaxis, andhematuria.Vital parameterswerenormal.
Blood tests were repeated, with evidence of severe thrombocyto-
penia (platelets, 5  103/L) and increased INR (1.77). Although a
more complete coagulationassay includingfibrinogen, antithrombin,
and D-dimer parameters was requested, the blood sample could not
be processed because of rapid blood clotting in the test tube. There-
fore, a platelet transfusion was given, which immediately resolved the
clinical problem. A new blood sample that was taken after 18 hours
showed an increase in the platelet count (33 103/L) and a decrease
in INR (1.32). Blood parameters had normalized by the next day.
WhereasNiuandMims1 investigated theactivityofADAMTS13,
we designed a method using the cytofluorimetric evaluation of anti-
CD61 (integrin beta-3) and PAC-1 binding to assess oxaliplatin-
induced platelet activation. PAC-1 is an antiplatelet antibody that is
capable of detecting fibrinogen receptor expression after the confor-
mational change of platelet glycoprotein IIb/IIIa.2 Such expression is
unique in the process of platelet activation. The analysis was per-
formedon three blood samples thatwere obtained from the patient at
different times after recovery from the acute event, and from three
healthy donors. PAC-1 and anti-CD61 bindingwas evaluated at base-
line and after 10minutes of in vitro contact betweenwhole blood and
oxaliplatin 0.5 mmol/L, simulating the concentration during the
courseof chemotherapy infusion.Figure1shows themainoutcomeof
the tests. Significant platelet activation (P .007) was observed after
exposure of the patient’s blood sample to the drug, whereas PAC-1
expression remained unchanged in the healthy donor samples
(P .43). The analysiswas repeatedusingfluorouracil (380mmol/L),
but without obtaining platelet activation.
Our findings show that, in our patient, oxaliplatin induced the
fibrinogen receptor exposure independently of the influence of the
endothelium. We agree with the conclusion of Niu and Mims1 that
the observed thrombocytopenia may have been caused by an
oxaliplatin-mediated autoimmune response. Other articles have also
focusedon thepresence—in somepatients—of serumantioxaliplatin
immunoglobulin G, which could represent the initial stimulus that is
needed for sudden platelet activation.3,4 Such an observation is con-
sistent with the fact that no cases of TTP have ever been reported
during the first cycle of FOLFOX.
Additionalstudiesareneededtoclarifywhetherthecytofluorimetric
assay of PAC-1 represents a valid and inexpensive method to assess im-
munologicsensitizationtooxaliplatinbeforeitsadministrationsothatthe
dramatic clinical impact of inducedTTP canbe avoided.
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